-
Figure 1 Belatacept mechanism of action
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Wojciechowski D, Vincenti F. Current status of costimulatory blockade in renal transplantation. Curr Opin Nephrol Hypertens 2016; 25:583–590. doi: 10.1097/MNH.0000000000000268
-
2.
Lentine KL, et al. OPTM/SRTR 2020 Annual Data Report: Kidney. Am J Transplant 2022; 22(Suppl 2):21–136. doi: 10.1111/ajt.16982
-
3.
Hariharan S, et al. Long-term survival after kidney transplantation. N Engl J Med 2021; 385:729–743. doi: 10.1056/NEJMra2014530
-
4.
Bertrand D, et al. Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrol Dial Transplant 2020; 35:336–345. doi: 10.1093/ndt/gfz255.
-
5.
Budde K, et al. Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: A randomized phase 3b trial. J Am Soc Nephrol 2021; 32:3252–3264. doi: 10.1681/ASN.2021050628
-
6.
El Hennawy H, et al. Belatacept rescue therapy of CNI-induced nephrotoxicity, meta-analysis. Transplant Rev (Orlando) 2021; 35:100653. doi: 10.1016/j.trre.2021.100653
-
7.
Adams AB, et al. Belatacept combined with transient calcineurin inhibitor therapy prevents rejection and promotes improved long-term renal allograft function. Am J Transplant 2017; 17:2922–2936. doi: 10.1111/ajt.14353
-
8.
Kaufman DB, et al. Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: Two-year results of a prospective, randomized multicenter trial. Clin J Am Soc Nephrol 2021; 16:1387–1397. doi: 10.2215/CJN.13100820
-
9.
Wojciechowski D, et al. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. Clin Transplant 2017; 31:e13042. doi: 10.1111/ctr.13042
-
10.
Schmitz R, et al. Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up. Am J Transplant 2020; 20:3609–3619. doi: 10.1111/ajt.16121
-
11.
Karadkhele G, et al. Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States. Clin Transplant 2022; 36:e14531. doi: 10.1111/ctr.14531
-
12.
Malvezzi P, et al. Switching renal transplant recipients to belatacept therapy: Results of a real-life gradual conversion protocol. Transpl Immunol 2019; 56:101207. doi: 10.1016/j.trim.2019.04.002
Updates on Belatacept in Kidney Transplantation
Jeffrey Kott
Jeffrey Kott
Jeffrey Kott, MD; Jorge Chancay, MD; and Fasika M. Tedla, MD, are with the Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Tedla is also with the Recanati/Miller Transplant Institute, Mount Sinai Hospital, New York, NY.
Search for other papers by Jeffrey Kott in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey Kott in
Current site
Google Scholar
PubMed
Jorge Chancay
Jorge Chancay
Jeffrey Kott, MD; Jorge Chancay, MD; and Fasika M. Tedla, MD, are with the Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Tedla is also with the Recanati/Miller Transplant Institute, Mount Sinai Hospital, New York, NY.
Search for other papers by Jorge Chancay in
Current site
Google Scholar
PubMed
Search for other papers by Jorge Chancay in
Current site
Google Scholar
PubMed
Fasika M. Tedla
Fasika M. Tedla
Jeffrey Kott, MD; Jorge Chancay, MD; and Fasika M. Tedla, MD, are with the Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Tedla is also with the Recanati/Miller Transplant Institute, Mount Sinai Hospital, New York, NY.
Search for other papers by Fasika M. Tedla in
Current site
Google Scholar
PubMed
Search for other papers by Fasika M. Tedla in
Current site
Google Scholar
PubMed
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory
Powered by PubFactory